James Oliviero
Fortune : 2 M $ au 30/06/2026
Fortune : 2 M $ au 30/06/2026
James F.
Oliviero is an Independent Director at Nuvectis Pharma, Inc. since 2021.
Formerly, Mr. Oliviero was President, Chief Executive Officer & Director at Checkpoint Therapeutics, Inc. from 2018 to 2025.
Mr. Oliviero was Finance Director at ACCESS Oncology, Inc. from 1999 to 2003.
Mr. Oliviero was Chief Financial Officer & Treasurer at Keryx Biopharmaceuticals, Inc. in 2015.
Mr. Oliviero completed undergraduate studies at Goizueta Business School-Emory.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUVECTIS PHARMA, INC. 0,46 % | 11/06/2026 | 122 828 ( 0,46 % ) | 2 M $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| NUVECTIS PHARMA, INC. | Directeur/Membre du Conseil | 01/07/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| CHECKPOINT THERAPEUTICS, INC. | Directeur Général | 30/05/2025 |
| KERYX BIOPHARMACEUTICALS | Directeur Financier/CFO | 01/09/2015 |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Develops pharmaceutical drugs | Directeur Financier/CFO | 01/05/2003 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Develops pharmaceutical drugs | Health Technology |
Goizueta Business School-Emory
Goizueta Business School-Emory Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national